Guideline decision tool · Oncology
🎗️

Endometrial Cancer Mayo Lymphadenectomy Indication — free guideline decision tool

Use the Mayo criteria (histology, grade, myometrial invasion, tumour size) to judge whether an endometrioid adenocarcinoma can safely be spared lymphadenectomy. Instant, browser-side.

Open guideline tool →
Computed locally — no data uploaded. For licensed clinicians.
📋

Guideline-based

Implements the decision logic from published clinical guidelines.

🖥️

Runs in your browser

No installation. Enter the patient's values and get a guideline recommendation instantly.

🔒

Data stays local

Nothing is uploaded. Results are for licensed clinicians only.

Worked calculation

The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.

HistologyEndometrioid adenocarcinoma
GradeG1–2
Myometrial invasion depthNo myometrial invasion (0%)
Maximum primary tumour diameter≤ 2 cm

LymphadenectomyCan be omitted

  • VerdictLow-risk: Endometrioid, no myometrial invasion (0%) — low-risk at any size/grade (nodal metastasis ~ 1–5%, 5-year survival ~ 99%)
  • Management directionSystematic pelvic/para-aortic lymphadenectomy can be safely omitted (no survival impact); sentinel-node mapping now commonly replaces it
  • NotesMayo criteria (Mariani 2000/2008): low-risk = endometrioid, G1–2, myometrial invasion ≤ 50%, diameter ≤ 2 cm (or no myometrial invasion, any size/grade); high-risk (> 50% invasion / G3 / > 2 cm / non-endometrioid) needs node assessment. Contemporary practice often replaces systematic dissection with sentinel-node biopsy
HistologyNon-endometrioid (serous/clear-cell/carcinosarcoma etc.)
GradeG3
Myometrial invasion depth> 50% (outer half)
Maximum primary tumour diameter> 2 cm

LymphadenectomyDissection/assessment advised

  • VerdictHigh-risk (at-risk): Non-endometrioid (serous/clear-cell/carcinosarcoma etc.) is high-risk histology and needs systematic staging / node assessment (nodal metastasis ~ 6.4%)
  • Management directionSystematic pelvic ± para-aortic lymphadenectomy is advised, or sentinel-node biopsy to complete staging
  • NotesMayo criteria (Mariani 2000/2008): low-risk = endometrioid, G1–2, myometrial invasion ≤ 50%, diameter ≤ 2 cm (or no myometrial invasion, any size/grade); high-risk (> 50% invasion / G3 / > 2 cm / non-endometrioid) needs node assessment. Contemporary practice often replaces systematic dissection with sentinel-node biopsy

Common questions

What is Endometrial Cancer Mayo Lymphadenectomy Indication?

Use the Mayo criteria (histology, grade, myometrial invasion, tumour size) to judge whether an endometrioid adenocarcinoma can safely be spared lymphadenectomy. Instant, browser-side.

How is Endometrial Cancer Mayo Lymphadenectomy Indication calculated? What is the core formula?

Low-risk = endometrioid, G1–2, myometrial invasion ≤ 50%, diameter ≤ 2 cm (or no myometrial invasion at any size/grade). Any of G3 / > 50% invasion / > 2 cm / non-endometrioid = at-risk.

When is Endometrial Cancer Mayo Lymphadenectomy Indication used?

Identify the low-risk endometrioid endometrial cancer group that can omit systematic lymphadenectomy.

What are the key clinical points for Endometrial Cancer Mayo Lymphadenectomy Indication?

The low-risk group has roughly 1–5% nodal metastasis and ~ 99% 5-year survival, and can omit systematic dissection without a survival cost. The at-risk group has roughly 6.4% nodal metastasis and warrants pelvic ± para-aortic dissection or sentinel-node biopsy. Non-endometrioid histology (serous/clear-cell/carcinosarcoma) is high-risk regardless and needs full staging. Contemporary practice increasingly replaces systematic lymphadenectomy with sentinel-node mapping.

What are the limits and cautions when using Endometrial Cancer Mayo Lymphadenectomy Indication?

For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.

How is Endometrial Cancer Mayo Lymphadenectomy Indication calculated in practice? Can you show a worked example?

Inputs: Histology Endometrioid adenocarcinoma, Grade G1–2, Myometrial invasion depth No myometrial invasion (0%), Maximum primary tumour diameter ≤ 2 cm → Result: Lymphadenectomy Can be omitted(Verdict: Low-risk: Endometrioid, no myometrial invasion (0%) — low-risk at any size/grade (nodal metastasis ~ 1–5%, 5-year survival ~ 99%), Management direction: Systematic pelvic/para-aortic lymphadenectomy can be safely omitted (no survival impact); sentinel-node mapping now commonly replaces it, Notes: Mayo criteria (Mariani 2000/2008): low-risk = endometrioid, G1–2, myometrial invasion ≤ 50%, diameter ≤ 2 cm (or no myometrial invasion, any size/grade); high-risk (> 50% invasion / G3 / > 2 cm / non-endometrioid) needs node assessment. Contemporary practice often replaces systematic dissection with sentinel-node biopsy) Inputs: Histology Non-endometrioid (serous/clear-cell/carcinosarcoma etc.), Grade G3, Myometrial invasion depth > 50% (outer half), Maximum primary tumour diameter > 2 cm → Result: Lymphadenectomy Dissection/assessment advised(Verdict: High-risk (at-risk): Non-endometrioid (serous/clear-cell/carcinosarcoma etc.) is high-risk histology and needs systematic staging / node assessment (nodal metastasis ~ 6.4%), Management direction: Systematic pelvic ± para-aortic lymphadenectomy is advised, or sentinel-node biopsy to complete staging, Notes: Mayo criteria (Mariani 2000/2008): low-risk = endometrioid, G1–2, myometrial invasion ≤ 50%, diameter ≤ 2 cm (or no myometrial invasion, any size/grade); high-risk (> 50% invasion / G3 / > 2 cm / non-endometrioid) needs node assessment. Contemporary practice often replaces systematic dissection with sentinel-node biopsy)

🎗️

Run Endometrial Cancer Mayo Lymphadenectomy Indication now

Use the Mayo criteria (histology, grade, myometrial invasion, tumour size) to judge whether an endometrioid adenocarcinoma can safely be spared lymphadenectomy. Instant, browser-side.

Open guideline tool →

For licensed clinicians. Not a substitute for clinical judgement.

Share on XLinkedInWhatsAppEmail

Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.

Related guideline tools

For use by licensed clinicians and clinical researchers. Computed locally in your browser — no data is uploaded. Not a substitute for clinical judgement.